Literature DB >> 11426565

Establishment of a human cell line (SKI-DLCL-1) with a t(1;14)(q21;q32) translocation from the ascites of a patient with diffuse large cell lymphoma.

A Goy1, F Gilles, Y Remache, D Filippa, C S Portlock, S C Jhanwar, A D Zelenetz.   

Abstract

Cytogenetic abnormalities at chromosome 1q21 are among the most common second genetic events observed in Non-Hodgkin's Lymphomas and have prognostic significance. Recently, BCL9 has been cloned from a pre-B-cell lymphoblastic leukemia cell line, which carried a t(1:14)(q21;q32). However, among a panel of 39 B-cell malignancies with 1q21 translocation, only two cases showed rearrangement for the BCL9 gene. We report the establishment of a new lymphoma cell line from a patient with relapsed diffuse large cell lymphoma. This cell line SKI-DLCL-1 showed cell surface antigens identical to the original tumor and demonstrated the profile of a mature B-cell phenotype: CD19 and CD20 positive, CD5 and C10 negative. It carried a t(1;14)(q21;q32) translocation identical to the original tumor. Although the clinical presentation was an isolated effusion lymphoma, studies for HIV-1, HHV8 and EBV were all negative. Southern blot analysis demonstrated that BCL9 was not rearranged in the SKI-DLCL-1 cell line. In addition, the BCL9 gene was not over-expressed in SKI-DLCL-1 cell line. The identification of a new locus at 1q21 will help clarify the pathogenesis of B-cell malignancies with a translocation involving this locus.

Entities:  

Mesh:

Year:  2001        PMID: 11426565     DOI: 10.3109/10428190109057942

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  2 in total

1.  Essential role of TAK1 in regulating mantle cell lymphoma survival.

Authors:  Daniela Buglio; Sangeetha Palakurthi; Kate Byth; Francisco Vega; Dorin Toader; Jamal Saeh; Sattva S Neelapu; Anas Younes
Journal:  Blood       Date:  2012-05-30       Impact factor: 22.113

2.  Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors.

Authors:  Annunziata Gloghini; Daniela Buglio; Noor M Khaskhely; Georgios Georgakis; Robert Z Orlowski; Sattva S Neelapu; Antonino Carbone; Anas Younes
Journal:  Br J Haematol       Date:  2009-09-22       Impact factor: 6.998

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.